Telomir Pharmaceuticals, Inc 8-K, filed Nov 21, 2024
Telomir Pharmaceuticals, Inc. (TELO)
About this 8-K
Telomir Pharmaceuticals, Inc filed this 8-K on November 21, 2024, reporting on events of November 18, 2024.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers
Resignation of Michael Jerman
On November 18, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the “Board”) and as Chair of the Audit Committee of the Company (the “Audit Committee”). Mr. Jerman’s resignation was due to his desire to pursue other activities, and not as a result of a disagreement with the Company.
Appointment of Dr. Matthew Del Giudice to the Audit Committee and Matthew Pratt Whalen as Chairman of the Audit Committee
On November 20, 2024, the Board of the Company unanimously approved the appointment of Dr. Matthew Del Giudice as a member of the Audit Committee, to fill the vacancy occasioned by the resignation of Mr. Jerman. The Board of the Company also unanimously approved the appointment of Matthew Pratt Whalen as the Chairman of the Audit Committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TELOMIR PHARMACEUTICALS, INC. | ||
| Date: November 21, 2024 | By: | /s/ Erez Aminov |
| Erez Aminov | ||
| Chief Financial Officer | ||